Literature DB >> 25365986

A theranostic "SMART" aptamer for targeted therapy of prostate cancer.

Vittorio de Franciscis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25365986      PMCID： PMC4429746          DOI： 10.1038/mt.2014.190

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

Review 1.  Monoclonal antibodies in cancer therapy.

Authors:  Andrew M Scott; James P Allison; Jedd D Wolchok
Journal:  Cancer Immun       Date:  2012-05-01

2.  Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.

Authors:  Rebecca E Conway; Nenad Petrovic; Zhong Li; Warren Heston; Dianqing Wu; Linda H Shapiro
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 3.  Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.

Authors:  Vittore Cereda; Vincenzo Formica; Gioia Massimiani; Livia Tosetto; Mario Roselli
Journal:  Expert Opin Investig Drugs       Date:  2014-02-03       Impact factor: 6.206

Review 4.  Targeting cancer cells with nucleic acid aptamers.

Authors:  Laura Cerchia; Vittorio de Franciscis
Journal:  Trends Biotechnol       Date:  2010-08-17       Impact factor: 19.536

5.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

6.  Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.

Authors:  Volker Baum; Patrick Bühler; Dorothee Gierschner; Dieter Herchenbach; Gina J Fiala; Wolfgang Wa Schamel; Philipp Wolf; Ursula Elsässer-Beile
Journal:  Immunotherapy       Date:  2013-01       Impact factor: 4.196

Review 7.  Antibody-drug conjugates targeting prostate-specific membrane antigen.

Authors:  William C Olson; Robert J Israel
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

8.  Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.

Authors:  Justin P Dassie; Luiza I Hernandez; Gregory S Thomas; Matthew E Long; William M Rockey; Craig A Howell; Yani Chen; Frank J Hernandez; Xiu Ying Liu; Mary E Wilson; Lee-Ann Allen; Daniel A Vaena; David K Meyerholz; Paloma H Giangrande
Journal:  Mol Ther       Date:  2014-06-23       Impact factor: 11.454

Review 9.  Aptamers as therapeutics.

Authors:  Anthony D Keefe; Supriya Pai; Andrew Ellington
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

10.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183
View more
  3 in total

1.  In vitro selection of DNA aptamers against human osteosarcoma.

Authors:  Khaliunsarnai Tsogtbaatar; Diana A Sousa; Debora Ferreira; Atakan Tevlek; Halil Murat Aydın; Eda Çelik; Ligia Rodrigues
Journal:  Invest New Drugs       Date:  2021-08-12       Impact factor: 3.850

Review 2.  Metal-Based PSMA Radioligands.

Authors:  Eleni Gourni; Gjermund Henriksen
Journal:  Molecules       Date:  2017-03-24       Impact factor: 4.411

Review 3.  Integrin Inhibitors in Prostate Cancer.

Authors:  Maylein C Juan-Rivera; Magaly Martínez-Ferrer
Journal:  Cancers (Basel)       Date:  2018-02-06       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.